Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Myeloid 2Lymphoid 2Genitourinary 2Gastrointestinal 2CNS 2

Conditions

Glioma 4Sarcoma 3Wilms Tumor 2Thyroid Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Multiple Myeloma 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Lung Neoplasms 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rectal Neoplasms 1

Interventions

Cyclophosphamide 9X-Rays 8Specimen Handling 8Phantoms, Imaging 7fludarabine 6Magnetic Resonance Spectroscopy 6cabozantinib 5Gemcitabine 5Biopsy 5Nuclear Medicine Department, Hospital 4Methotrexate 4Doxorubicin 4fludarabine phosphate 3Ifosfamide 3Cisplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2mifamurtide 2larotrectinib 2ivosidenib 2irinotecan sucrosofate 2ensartinib 2atezolizumab 2Vincristine 2Temozolomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Osteosarcoma × larotrectinib × 90 days × Clear all
NCT03213704 2026-06-02

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
9 enrolled 12 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
1,377 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡